Perigon Wealth Management
VRTX icon

Perigon Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Perigon Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.96M Sell
7,574
-1,260
-14% -$645K 0.06% 259
2026
Q2 		$4.39M Buy
8,834
+2,380
+37% +$1.05M 0.07% 253
2026
Q1 		$2.88M Buy
6,454
+410
+7% +$191K 0.05% 303
2025
Q4 		$2.74M Sell
6,044
-64
-1% -$27.6K 0.05% 304
2025
Q3 		$2.39M Buy
6,108
+104
+2% +$43.5K 0.05% 311
2025
Q2 		$2.67M Buy
6,004
+724
+14% +$334K 0.06% 281
2025
Q1 		$2.56M Buy
5,280
+337
+7% +$157K 0.07% 270
2024
Q4 		$2.06M Buy
4,943
+94
+2% +$43.6K 0.05% 304
2024
Q3 		$2.26M Buy
+4,849
New +$2.33M 0.06% 270
2024
Q1 		– Sell
-1,432
Closed -$583K – 906
2023
Q4 		$583K Buy
1,432
+8
+0.6% +$2.96K 0.02% 459
2023
Q3 		$495K Sell
1,424
-124
-8% -$43.4K 0.02% 447
2023
Q2 		$545K Buy
1,548
+216
+16% +$72.8K 0.02% 438
2023
Q1 		$420K Sell
1,332
-407
-23% -$122K 0.02% 434
2022
Q4 		$502K Buy
1,739
+147
+9% +$44.8K 0.03% 387
2022
Q3 		$461K Sell
1,592
-1,038
-39% -$299K 0.04% 346
2022
Q2 		$741K Sell
2,630
-1,011
-28% -$271K 0.06% 254
2022
Q1 		$950K Buy
3,641
+526
+17% +$125K 0.07% 240
2021
Q4 		$684K Buy
3,115
+444
+17% +$86.3K 0.05% 279
2021
Q3 		$484K Sell
2,671
-469
-15% -$91.6K 0.04% 311
2021
Q2 		$633K Buy
3,140
+996
+46% +$208K 0.06% 261
2021
Q1 		$461K Buy
2,144
+1,403
+189% +$308K 0.05% 308
2020
Q4 		$175K Buy
+741
New +$170K 0.02% 418
2018
Q2 		– Sell
-65
Closed -$11K – 585
2018
Q1 		$11K Hold
65
– – ﹤0.01% 507
2017
Q4 		$10K Hold
65
– – ﹤0.01% 493
2017
Q3 		$10K Buy
+65
New +$9.8K ﹤0.01% 513

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
AMF Tjänstepension
AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Montrusco Bolton Investments
Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return
Birch Hill Investment Advisors
Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
ABN AMRO Investment Solutions
ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

Perigon Wealth Management's VRTX Position: Q3 2026 in Review

Perigon Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 14% in Q3 2026, selling an estimated $645K and leaving 7,574 shares worth $3.96M. The position accounts for 0.06% of the portfolio, ranked #259.

Perigon Wealth Management first reported a position in VRTX in Q3 2017 and has held it in 25 quarters since. The position peaked at $4.39M in Q2 2026. 443 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Perigon Wealth Management held 7,574 shares of Vertex Pharmaceuticals worth $3.96M as of Q3 2026.
  • Perigon Wealth Management sold 1,260 Vertex Pharmaceuticals shares in Q3 2026, an estimated $645K.
  • Vertex Pharmaceuticals made up 0.06% of Perigon Wealth Management's portfolio in Q3 2026, its #259 holding.
  • Perigon Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 25 quarters since.
  • Perigon Wealth Management's Vertex Pharmaceuticals position peaked at $4.39M in Q2 2026.
  • 443 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Perigon Wealth Management's 13F filing for Q3 2026, filed 22 Oct 2026.